Currently, there are 302.79M common shares owned by the public and among those 277.90M shares have been available to trade.
The company’s stock has a 5-day price change of 12.25% and 26.61% over the past three months. EXEL shares are trading 18.80% year to date (YTD), with the 12-month market performance up to 33.43% higher. It has a 12-month low price of $18.64 and touched a high of $27.83 over the same period. EXEL has an average intraday trading volume of 1.75 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 8.28%, 8.62%, and 22.38% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Exelixis Inc (NASDAQ: EXEL) shares accounts for 86.06% of the company’s 302.79M shares outstanding.
It has a market capitalization of $8.13B and a beta (3y monthly) value of 0.55. The stock’s trailing 12-month PE ratio is 24.40, while the earnings-per-share (ttm) stands at $1.17. The company has a PEG of 0.82 and a Quick Ratio of 4.21 with the debt-to-equity ratio at 0.09. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.74% over the week and 2.60% over the month.
Earnings per share for the fiscal year are expected to increase by 133.94%, and -3.31% over the next financial year. EPS should grow at an annualized rate of 29.92% over the next five years, compared to -21.77% over the past 5-year period.
Looking at the support for the EXEL, a number of firms have released research notes about the stock. UBS stated their Neutral rating for the stock in a research note on September 19, 2024, with the firm’s price target at $30. Barclays coverage for the Exelixis Inc (EXEL) stock in a research note released on April 11, 2024 offered a Equal Weight rating with a price target of $25. BTIG Research was of a view on December 19, 2023 that the stock is Buy, while Citigroup gave the stock Buy rating on December 15, 2023, issuing a price target of $31. H.C. Wainwright on their part issued Buy rating on September 26, 2023.
